Evidence Grade D — Primarily preclinical. 21 published studies, mostly animal models. 6 registered clinical trials.
Medically reviewed by a licensed medical professional
Argireline is a synthetic hexapeptide widely used in cosmetic skincare as a topical alternative to Botox for reducing expression lines. Marketed as 'Acetyl Hexapeptide-8', it appears in numerous anti-ageing creams and serums. It has no pharmaceutical approval. A key scientific question is whether enough peptide can penetrate intact skin to reach the muscle junctions where it would need to act.
Argireline is also known by these brand and alternate names:
21 published studies: 9 human, 2 animal, 4 in-vitro, 2 reviews
Argireline has no pharmaceutical authorisation. It is widely available as a cosmetic ingredient in over-the-counter skincare products. Small industry-sponsored studies have reported wrinkle depth reductions of 17–30% with topical application.
The key scientific question is whether sufficient peptide penetrates intact skin to reach neuromuscular junctions and produce a meaningful effect. The molecule's size exceeds the conventional limit for transdermal absorption. Argireline's cosmetic use in formulated skincare products represents a fundamentally different risk profile from injectable use.
Research suggests Argireline inhibits the SNARE complex — the molecular machinery that nerve endings use to release the signalling molecule acetylcholine at muscle junctions. By reducing acetylcholine release, the theory is that facial muscles contract less strongly, reducing expression lines. A critical limitation is that at nearly 889 Da, the molecule exceeds the generally accepted size limit for skin penetration (500 Da), and studies report very low absorption rates.
Research suggests small industry-sponsored studies have reported wrinkle depth reductions of 17-30% with topical application. The molecular mechanism (inhibiting the SNARE complex that controls muscle signalling) is well-characterised in laboratory settings. However, a 2025 systematic review found that no dedicated double-blind trials exist. The molecule exceeds the generally accepted size limit for skin penetration (889 Da versus the 500 Da threshold), and studies report very low absorption rates (under 0.2%). Combined with its 4,286-fold lower potency compared to botulinum toxin, serious questions remain about whether biologically meaningful concentrations reach the target site through topical application alone.
PeptideTrace tracks 6 registered clinical trials for Argireline sourced from ClinicalTrials.gov.
A Clinical Trial to Evaluate the Effects of an Eye Serum on Improving the Appearance of the Periorbital Area
Investigating the Wrinkle Reduction Potential of a Novel Compounded Skin Care Cream
Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin
Acetyl Hexapeptide-8 for Blepharospasm
A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm
Argireline (Acetyl Hexapeptide-3/Acetyl Hexapeptide-8) is a 6-amino acid synthetic peptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2. Its molecular weight is 888.99 Da (CAS 616204-22-9). Developed by Lipotec (now Lubrizol), Argireline was designed as a topical alternative to botulinum toxin for reducing expression lines. It mimics the N-terminus of SNAP-25, a protein component of the SNARE complex required for neurotransmitter release. The compound is widely used in cosmetic formulations marketed for wrinkle reduction, though its efficacy is limited by poor skin penetration (<0.2% after 24 hours).
Research suggests Argireline acts as a competitive inhibitor of SNARE complex assembly. It mimics the N-terminal portion of SNAP-25 and competes with native SNAP-25 for binding to the SNARE complex components (syntaxin and VAMP/synaptobrevin). By preventing complete SNARE complex formation, it reduces vesicle fusion and acetylcholine release at the neuromuscular junction, producing localized muscle relaxation. The IC50 for SNARE inhibition is approximately 110 microM, compared to botulinum toxin type A IC50 of 0.026 microM, making Argireline approximately 4,286 times less potent than BoNT-A at the molecular level.
An industry-sponsored study (N=10) reported 30% wrinkle depth reduction with Argireline application. A larger unblinded RCT (N=60, 3:1 allocation) reported 48.9% efficacy versus 0% placebo (p<0.01). A critical limitation is skin penetration: at 889 Da, Argireline exceeds the 500 Da rule for transdermal absorption, with only approximately 0.01% reaching the epidermis after 24 hours of topical application. A 2025 systematic review concluded that no dedicated double-blind clinical trials evaluating cosmetic anti-wrinkle efficacy currently exist for Argireline, and all published data are industry-sponsored.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 3 vendor listings
View pricing data across vendors and countries for Argireline
GHK has no pharmaceutical authorisation. Small cosmetic studies of the copper-complexed form (GHK-Cu) have reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable use have been completed. As with GHK-Cu (#85), the cosmetic evidence base for topical use should be distinguished from claims about injectable use. Gene expression profiling studies have reported broad effects, but observational genomic changes do not constitute evidence of therapeutic efficacy. This entry overlaps substantially with GHK-Cu (#85).
GHK-Cu has no pharmaceutical authorisation from any regulatory agency. It is widely available as a cosmetic ingredient in over-the-counter skincare products, where it is marketed for skin conditioning. A small study comparing GHK-Cu cream to vitamin C and retinoic acid creams reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable GHK-Cu have been completed. The compound's cosmetic use (topical, in formulated skincare products) should be clearly distinguished from its unregulated availability as an injectable research compound. These represent fundamentally different risk profiles.
Matrixyl 3000 has no pharmaceutical authorisation. It is widely used as a cosmetic ingredient. Small studies report wrinkle reduction, with a head-to-head comparison against the original Matrixyl suggesting greater statistical significance on wrinkle endpoints. As a two-component combination, Matrixyl 3000's evidence should be interpreted alongside the individual component entries: Palmitoyl Tripeptide-1 (#139) and Palmitoyl Tetrapeptide-7 (#140). It is a topical cosmetic ingredient.
Evidence Reviews
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
